1021912-42-4
1021912-42-4 structure
- Name: TC-G 1003
- Chemical Name: 3-[4-(3-aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)quinolin-6-yl]phenol
- CAS Number: 1021912-42-4
- Molecular Formula: C26H25ClN2O2
- Molecular Weight: 432.94200
- Catalog: Signaling Pathways GPCR/G Protein Somatostatin Receptor
- Create Date: 2018-01-22 04:32:10
- Modify Date: 2024-06-21 16:16:43
-
sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst2) agonist with a Ki value of 0.025 nM and a cAMP IC50 value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect[1].
| Name | 3-[4-(3-aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)quinolin-6-yl]phenol |
|---|---|
| Synonyms | 3-[4-(3-aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)-quinolin-6-yl]phenol |
| Description | sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst2) agonist with a Ki value of 0.025 nM and a cAMP IC50 value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect[1]. |
|---|---|
| Related Catalog | |
| Target |
sst2:0.025 nM (Ki) sst2:4.8 nM (IC50) |
| In Vivo | sst2 Receptor agonist-1 (compound 21) (0.2 or 2 mg/kg; IV; single dosage) shows a dose-dependent decrease in growth hormone (GH) secretion[1]. sst2 Receptor agonist-1 (5 or 15 μg/per eye; intraocular; once every 4 days) reduces neovascular lesion area in laser choroidal neovascularization (CNV) rat model[1]. Pharmacokinetic Parameters of sst2 Receptor agonist-1 (compound 21) in dogs and rats[1]. species dog (IV 0.125 mg/kg) rat (IV 2 mg/kg or 5 mg/kg) CLplasma (mL/min/kg) 7.1 52 t1/2 (h) 11 2.9 VdSS (L/kg) 5.7 9.4 F (%) ND 17 Animal Model: Female Wistar rats (200-250 g; IP injection with 50 mg/kg pentobarbital, then injected with tested compound via jugular cannula, after 40 or 50 min administration, injected with GH secretagogue via jugular cannula)[1] Dosage: 0.2 or 2 mg/kg Administration: IV; single dosage Result: Caused a dose-dependent decrease in GH secretion (38 and 91% reduction in plasma GH AUC following administration of 0.2 and 2 mg/kg, respectively). Animal Model: Male Brown Norway rats (175-225 g; lasered and perfused, a 27G needle was used to make a small hole in the eye 3 mm posterior to iris angled 45° toward the optic nerve)[1] Dosage: 5 or 15 μg/per eye, 5 μL Administration: Intraocular administration; inject at day 0, 4 and 8 Result: Exhibited a dose-dependent antiangiogenic effect by a 35 and 53% reduction in neovascular lesion area with 5 or 15 μg per eye, respectively. |
| References |
| Molecular Formula | C26H25ClN2O2 |
|---|---|
| Molecular Weight | 432.94200 |
| Exact Mass | 432.16000 |
| PSA | 68.37000 |
| LogP | 6.97250 |